Uni Eropa - Lituavi - EMA (European Medicines Agency)

biosimilar collaborations ireland limited - adalimumabas - hidradenitis suppurativa; psoriasis; uveitis; arthritis, rheumatoid; spondylitis, ankylosing; crohn disease; colitis, ulcerative; arthritis, psoriatic - imunosupresantais, naviko nekrozės faktoriaus alfa (tnf-α) inhibitoriai

Uni Eropa - Lituavi - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - adalimumabas - arthritis, rheumatoid; arthritis, psoriatic; psoriasis; spondylitis, ankylosing; uveitis; hidradenitis suppurativa; colitis, ulcerative; crohn disease; arthritis, juvenile rheumatoid - imunosupresantai - rheumatoid arthritisyuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. adalimumabas buvo įrodyta, kad sumažinti greitį progresavimą, bendrą žalą, vertinant pagal x-ray ir gerinti fizinę funkciją, skiriant kartu su metotreksatu. juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritisyuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5. adalimumabas nebuvo tirtas pacientams, jaunesniems negu 2 metų. enthesitis-related arthritisyuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritisankylosing spondylitis (as)yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of asyuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). psoriatic arthritisyuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. adalimumabas buvo įrodyta, kad sumažinti greitį progresavimą, periferinių sąnarių pažeidimai, kaip matuojamas x-ray sergant poliartritu simetriškus potipių ligos (žr. skyrių 5. 1), ir gerinti fizinę funkcija. psoriasisyuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasisyuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 ir 5. crohn’s diseaseyuflyma is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseaseyuflyma is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitisyuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. paediatric ulcerative colitisyuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitisyuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitisyuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Uni Eropa - Lituavi - EMA (European Medicines Agency)

stada arzneimittel ag - adalimumabas - arthritis, psoriatic; arthritis, juvenile rheumatoid; arthritis, rheumatoid; colitis, ulcerative; crohn disease; hidradenitis suppurativa; psoriasis; spondylitis, ankylosing; uveitis - imunosupresantai - rheumatoid arthritishukyndra in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs (dmards) including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. hukyndra can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. adalimumabas buvo įrodyta, kad sumažinti greitį progresavimą, bendrą žalą, vertinant pagal x-ray ir gerinti fizinę funkciją, skiriant kartu su metotreksatu. juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritishukyndra in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more dmard. hukyndra can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5. adalimumabas nebuvo tirtas pacientams, jaunesniems negu 2 metų. enthesitis-related arthritishukyndra is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritisankylosing spondylitis (as)hukyndra is indicated for the treatment of adults with severe active as who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of ashukyndra is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (nsaids). psoriatic arthritishukyndra is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous dmard therapy has been inadequate. adalimumabas buvo įrodyta, kad sumažinti greitį progresavimą, periferinių sąnarių pažeidimai, kaip matuojamas x-ray sergant poliartritu simetriškus potipių ligos (žr. skyrių 5. 1), ir gerinti fizinę funkcija. psoriasishukyndra is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasishukyndra is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)hukyndra is indicated for the treatment of active moderate to severe hs (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 ir 5. crohn’s diseasehukyndra is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseasehukyndra is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitishukyndra is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. paediatric ulcerative colitishukyndra is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitishukyndra is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitishukyndra is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Uni Eropa - Lituavi - EMA (European Medicines Agency)

stada arzneimittel ag - adalimumabas - arthritis, rheumatoid; arthritis, juvenile rheumatoid; spondylitis, ankylosing; arthritis, psoriatic; psoriasis; hidradenitis suppurativa; crohn disease; colitis, ulcerative; uveitis - imunosupresantai - rheumatoid arthritislibmyris in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs (dmards) including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. libmyris can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. adalimumabas buvo įrodyta, kad sumažinti greitį progresavimą, bendrą žalą, vertinant pagal x-ray ir gerinti fizinę funkciją, skiriant kartu su metotreksatu. juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritislibmyris in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more dmard. libmyris can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5. adalimumabas nebuvo tirtas pacientams, jaunesniems negu 2 metų. enthesitis-related arthritislibmyris is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. axial spondyloarthritisankylosing spondylitis (as)libmyris is indicated for the treatment of adults with severe active as who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of aslibmyris is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (nsaids). psoriatic arthritislibmyris is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous dmard therapy has been inadequate. adalimumabas buvo įrodyta, kad sumažinti greitį progresavimą, periferinių sąnarių pažeidimai, kaip matuojamas x-ray sergant poliartritu simetriškus potipius ligą ir pagerinti fizinį funkcija. psoriasislibmyris is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasislibmyris is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)libmyris is indicated for the treatment of active moderate to severe hs (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 ir 5. crohn’s diseaselibmyris is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseaselibmyris is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitislibmyris is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. paediatric ulcerative colitislibmyris is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitislibmyris is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitislibmyris is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Lituania - Lituavi - SMCA (Valstybinė vaistų kontrolės tarnyba)

kemira oyj, porkkalankatu 3, p. o. box 330 00101 helsinki (suomija). - glutaralis, glutaro aldehidas, 1,5-pentandialis - veikliosios medžiagos cas nr.: 111-30-8, eb nr.: 203-856-5, veikliosios medžiagos pavadinimas: glutaralis, glutaro aldehidas, 1,5-pentandialis, koncentracija: 50% , veiklioji - slimicidai

Lituania - Lituavi - SMCA (Valstybinė vaistų kontrolės tarnyba)

kemira oyj, porkkalankatu 3, p. o. box 330 00101 helsinki (suomija). - 2,2-dibrom-3-nitrilpropionamidas; 2,2-dibrom-3-nitrilpropionamidas; 2,2-dibrom-3-nitrilpropionamidas - veikliosios medžiagos cas nr.: 10222-01-2, eb nr.: 233-539-7, veikliosios medžiagos pavadinimas: 2,2-dibrom-3-nitrilpropionamidas, koncentracija: 12% , veiklioji; veikliosios medžiagos cas nr.: 10222-01-2, eb nr.: 233-539-7, veikliosios medžiagos pavadinimas: 2,2-dibrom-3-nitrilpropionamidas, koncentracija: 12% , veiklioji; veikliosios medžiagos cas nr.: 10222-01-2, eb nr.: 233-539-7, veikliosios medžiagos pavadinimas: 2,2-dibrom-3-nitrilpropionamidas, koncentracija: 12% , veiklioji - slimicidai

Lituania - Lituavi - SMCA (Valstybinė vaistų kontrolės tarnyba)

kemira oyj, energiakatu 4, p. o. box 330 00180 helsinki (suomija). - 5-chlor-2-metil-4-izotiazol-3(2h)-ono ir 2-metil-3(2h)-izotiazolono mišinys (3:1) - veikliosios medžiagos cas nr.: 55965-84-9, eb nr.: -, veikliosios medžiagos pavadinimas: 5-chlor-2-metil-4-izotiazol-3(2h)-ono ir 2-metil-3(2h)-izotiazolono mišinys (3:1), koncentracija: 2.03% , veiklioji - slimicidai

Uni Eropa - Lituavi - EMA (European Medicines Agency)

intervet international bv - ibafloksacinas - antibakteriniai preparatai sisteminiam naudojimui - dogs; cats - Šunys:ibaflin fluorouracilu ir folino nurodytų sąlygų šunys:odos infekcija (pyoderma - paviršinių ir giliųjų, žaizdų, pūlinių) sukelia jautrios padermės, stafilokokai, escherichia coli ir proteus mirabilis;ūmus, nekomplikuota šlapimo-takų infekcijos, kurią sukėlė jautrios padermės, stafilokokai, proteus rūšys, enterobacter spp. , e.. coli ir klebsiella spp. ;kvėpavimo takų infekcijomis (viršutinių takų) sukelia jautrios padermės stafilokokų, e. coli ir klebsiella spp. ibaflin gelis yra nurodyta šunims gydyti šias sąlygas:odos infekcija (pyoderma - paviršinių ir giliųjų, žaizdų, pūlinių) sukelia jautrūs patogenų, tokių kaip staphylococcus spp. , e.. coli ir p. mirabilis. katės:ibaflin gelis yra nurodyta kačių gydymas iš šių sąlygų:odos infekcijos, minkštųjų audinių infekcijos; - žaizdų, pūlinių) sukelia jautrūs patogenų, tokių kaip staphylococcus spp. , e.. coli, proteus spp. ir pasteurella spp. ;viršutinių kvėpavimo takų infekcijų, kurias sukelia jautrūs patogenų, tokių kaip staphylococcus spp. , e.. coli, klebsiella spp. ir pasteurella spp.

Lituania - Lituavi - Adama

adama - koncentruota emulsija/koncentruota suspensija - azoksistrobinas + protiokonazolas - fungicidai

Lituania - Lituavi - SMCA (Valstybinė vaistų kontrolės tarnyba)

richard bittner ag - mana (manna)/kamparas, raceminis (camphora)/geltonųjų ciberžolių (zedoariae) šaknys/vaistinių šventagaršvių (angelicae archangelicae) šaknys/mira (myrrha)/geltonųjų gencijonų (gentianae) šaknys/kvapniųjų muskatmedžių (myristicae) sėklos/bestiebių karlinų (carlinae) šaknys/pilkųjų saldymedžių (liquiritae) šaknys/didžiųjų debesylų (helenii) šaknys/Širdažolių (centaurii) žolė/gvazdikėlių (caryophylli) žiedai/vaistinių alpinijų (galangae) šaknys/imbierų (zingiberis) šaknys/karčiųjų šventadagių (cardui benedicti) žolė/kraujažolių (achillea moschata) žolė/teriakas (theriak)/vilkdalgių (iridis) šaknys/tūbių (verbasci) žiedai/karčiojo citrinmedžio (pericarpium aurantii) apyvaisiai/ajerų (calami) šaknys/karčiųjų kiečių (artemisia absinthium) žolė/kurakao (curacao) žievė/kubebinių pipirų (cubebae) vaisiai/Žvaigždanyžių (anisi stellati) vaisiai/saldžiavaisių citrinmedžių (aurantii dulcis) apyvaisiai/trilapių pupalaiškių (menyanthidis) lapai - geriamasis tirpalas - 1,36 mg/0,95 mg/1,38 mg/1,36 mg/0,7 mg/0,5 mg/0,28 mg/0,68 mg/0,17 mg/0,02 mg/0,013 mg/0,03 mg/0,014 mg/0,015 mg/0,015 mg/0,006 mg/0,97 mg/0,005 mg/0,014 mg/0,031 mg/0,047 mg/0,035 mg/0,038 mg/0,017 mg/0,046 mg/0,011 mg/0,12 mg/ml; 1,36 mg/0,95 mg/1,38 mg/1,36 mg/0,7 mg/0,5 mg/0,28 mg/0,68 mg/0,17 mg/0,02 mg/0,013 mg/0,03 mg/0,014 mg/0,015 mg/0,015 mg/0,006 - other alimentary tract and metabolism products